Trials
Search / Trial NCT06441409

Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease

Launched by THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · May 28, 2024

Trial Information

Current as of February 19, 2025

Completed

Keywords

ClinConnect Summary

The diagnosis of MASLD was based on MRI. The diet scheme was formulated based on the results of body composition analysis.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • age between 18 and 80 years outpatients
  • Exclusion Criteria:
  • previous diagnosis of diabetes acute and chronic complications acute and chronic inflammation long-term history of heavy alcohol consumption

Trial Officials

Ping Jin

Study Chair

The Third Xiangya Hospital of Central South University

About The Third Xiangya Hospital Of Central South University

The Third Xiangya Hospital of Central South University is a leading academic medical institution in China, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital focuses on a wide range of medical disciplines, emphasizing patient-centered approaches and evidence-based practices. With a commitment to improving treatment outcomes and enhancing patient care, the hospital collaborates with a diverse network of researchers and healthcare professionals, aiming to contribute significantly to the global medical community through rigorous scientific inquiry and high-quality clinical studies.

Locations

Changsha, Hunan, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0